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Summary 
A murine monodonal antibody (M31-15) was identified using the penetration-inhibiting  assay 
of a human lung adenocarcinoma cell line (MAC10) and remarkably inhibited the phagokinetic 
tract motility of various cancer cell lines. The antigen, motility-related protein (MRP-1), recognized 
by M31-15, was 25- and 28-kD proteins,  and M31-15 was used to isolate a cDNA clone from 
a human breast carcinoma cDNA library.  Sequence analysis  revealed that  MRP-1 had strong 
similarity with a B cell surface antigen  (CD37),  a melanoma-associated  antigen  (ME491),  the 
target of an antiproliferative antibody (TAPA-1),  a human tumor-associated antigen (CO-029), 
and the Sm23 antigen  of the trematode parasite Schistosoma  mansoni. 
C 
ell motility is a highly complex process dependent on 
pericellular  adhesion  molecules  such  as  fibronectin 
(FN) 1 and  laminin,  their  integrin  receptors,  cytoskeletal 
components,  and a junctional  unit connecting cytoskeletal 
components and membrane receptors (1, 2). Involvement of 
the  cell-binding  and  Hep-2  domains  of FN  and  integrin 
receptor in determining cell motility for certain types of cells 
has become increasingly clear (3). In addition, a large variety 
of growth factors and autocrine factors have been shown to 
stimulate cell motility (4). There has been little attention paid 
to carbohydrates that modulate cell motility despite the fact 
that cell surface proteins and lipids are heavily glycosylated. 
Recently, we (5) showed that two independent mAbs directed 
to a common carbohydrate structure, Fuca 1-2Galfll-K, dra- 
matically inhibited the motility of various cancer cell lines 
and metastasis  of BL6 (6), highly metastatic variants of mouse 
melanoma B16.  To identify cell surface molecules involved 
in the control of cell motility, we described a new approach 
based on: (a) selection of a few lines showing high motility 
out of a large number of human tumor cell lines; (b) immu- 
nization of mice with the high-motility cell lines and selec- 
tion of mAbs showing inhibition of cell motility in polycar- 
bonate membrane penetration assay; and (c) characterization 
of the  epitope defined by motility-inhibiting  mAbs.  This 
procedure has led us to an interesting mAb, M31-15, which 
recognized 25- and 28-kD cell surface proteins called motility- 
1  Abbreviations used in this paper: FN, fibronectin; MRP-1, motility related 
protein. 
related protein (MRP-1). A cDNA clone for MRP-1 was iso- 
lated from a human breast carcinoma cDNA library with this 
antibody, and the amino acid sequence of MRP-1 was predicted 
from  the cDNA  sequence. 
Materials and Methods 
Determination of CellMotility.  Cell motility was determined by 
two assay systems, cell penetration (5) and phagokinetic track (7). 
In the former  system, cell migration  was determined  through a 
polycarbonate membrane assembly based on a Boyden chamber (1, 
8). The assembly (Transwell) was purchased from Costar (Cam- 
bridge, MA) with defined pore size (3-, 5-, and 8-#m diameter). 
Briefly, 100-/zl hybridoma  supernatant  containing  a known con- 
centration  of mAb was mixed with 600 #1 of culture medium in 
the lower Transwell compartment,  and 105 cells were placed in the 
upper chamber and cultured  for 16 h. Cells penetrating  into the 
lower chamber, found mostly (95%) at the bottom of the lower 
compartment,  were then counted. In the phagokinetic tract assay, 
cell motility was determined  on the basis of phagokinetic  tracts 
on gold particle-coated plate (7). Uniform carpets of gold particles 
were prepared on glass coverslips coated with BSA, and the cover- 
slips were rinsed extensively to remove nonadhering or loose gold 
particles before cell plating.  1,000-2,000 freshly trypsinized cells 
were plated in a 3.5-cm plastic dish (Falcon Labware, Oxford, CA) 
and left in the incubator for 16 h. Phagokinetic tracks were visual- 
ized in dark-field microscopy at low power by using side illumina- 
tion. Gold particles were detected as dark dots. Pictures were taken, 
areas cleared by a single cultured cell were traced on semitransparent 
paper of uniform thickness, and average areas were calculated (9). 
Since this method only measures minimum  motility,  it was used 
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hand, motility of many types of cells cannot be measured  by penetra- 
tion assay, since these cells hardly migrate through polycarbonate 
membrane. However, motility of most these cells can be measured 
easily by phagokinetic track assay. 
Selection of mAbs Displaying lnhibition of Cell Motility.  Initially, 
cell motility of ;>120 human tumor cell lines was examined  by the 
penetration assay  described above. Only a few lines were found to 
be  highly  motile:  U937 (histiocytic  lymphoma)  (10), HEL 
(erythroleukemia) (11), and MAC10 (lung adenocarcinoma) (5). 
U937 and HEL were able to penetrate Transwell membranes with 
pore diameters of 3/zm, and MAC10 can do 5/~m, respectively. 
All other tumor cell lines tested were less motile, and normal cells 
were immotile. Initially, mice  were immunized with MAC10 cells 
and a few mAbs inhibiting MAC10 motility were obtained, but 
all of these antibodies were detecting specific epitopes that only 
MAC10 cells had. We could not find any other cancer cell lines 
on which such epitopes were expressed. As we wanted to find new 
motility-inhibiting factors that were common to many kinds of 
solid cancer cell lines, we decided to immunize mice with cancer 
cells different  from MAC10 to be used for the TransweU  penetrating 
assay. Subsequently,  mice were immunized with MAC8 (lung ade- 
nocarcinoma), which originated from brain metastatic lesion, and 
their splenocytes  were fused with HAT-sensitive  mouse myeloma 
cell line SP2 as described previously (12). Antibody-secreting hy- 
bridomas were selected on the basis of their ability to inhibit cell 
motility (see above) in the motile cell lines. Inhibition of cell mo- 
tility was expressed as the reduction of the number of cells able 
to penetrate the polycarbonate membrane. 
Determination  ofmAb Specificity.  Glycolipids  were extracted from 
MAC10 cells with isopropanol/hexane/water  (55:20:25; vol/vol/vol) 
(13) and partitioned according  to Folch-Pi  et al. (14). The glycolipids 
in the upper layer fraction of the Folch-Pi's partition were sub- 
jected to DEAE Sephadex A-25 (Pharmacia Fine Chemicals, Upp- 
sala, Sweden) column chromatography.  After the neutral glycolipids 
were eluted with chloroform/methanol/water  (30:60:8; vol/vol/ 
vol), gangliosides were eluted with chloroform/methanol/0.8  N 
sodium acetate (30:60:8; vol/vol/vol) (15). Such two-mixture frac- 
tions were used in the ELISA and TIC immunostaining method 
without further purification (16, 17). The antibodies selected  were 
tested against extracted glycolipids  coated on plastic plates, as well 
as protein (or glycoprotein) in the cellular extracts with 1% triton 
X-100 coated on plastic surface and tested for antibody binding. 
Some of mAbs selected based on inhibition of cell motility were 
found to bind glycolipids,  while others bound glycoproteins  or pro- 
teins. Glycoprotein  or protein antigens were also characterized  after 
cells were extracted with Laemmli's sample buffer (18) followed 
by slab gel electrophoresis, Western blotting, and immunostaining 
(19). Alternatively, cells were washed with 0.1  M Tris/10 mM 
EDTA/0.2 mM (p-amidinophenyl)  methansulfonyl  fluoride  (pH 8.1) 
and solubilized with 1% CHAPS in the above buffer for 2 h on 
ice. Insoluble materials were removed by centrifugation,  and an 
aliquot of the soluble fraction was subjected to slab gel electropho- 
resis followed by Western blotting and immunostaining (18, 19). 
Antibody Binding to Various Cell Lines.  A variety of motile and 
immotile human cell lines, as well as high-metastatic (BL6) and 
low-metastatic (FI) variants of mouse melanoma cell line B16 (6, 
20), were tested  by immunofluorescence  with FITC-conjugated  goat 
anti-mouse IgG (Tago Inc., Burlingame, CA) and by cytofluorom- 
etry (21). 
Immunohistochemical  Techniques.  The avidin-biotin  complex  tech- 
niques for immunohistochemical study of various kinds of cancers 
was performed as follows (22): tumor sections of 4-/~m thickness 
were made free of para~n by soaking in xylene and dehydrating 
in graded ethanol. The endogenous peroxidase  activity was blocked 
by treating the sections with 0.3% hydrogen peroxide for 20 min. 
After washing for 5 rain in 50 mM Tris buffer, pH 7.4, the sections 
were incubated for 2 h at room temperature with normal horse 
serum and then exposed overnight to the culture supernatant of 
the produced hybridoma. After washing in 50 mM tris buffer for 
20 min, the sections were treated for 2 h with the solution of bi- 
otinylated horse anti-mouse IgG, washed again for 20 min, and 
treated for I h with PBS that contained the avidin-biotin complex. 
After washing in 50 mM Tris buffer for 30 min, the sections were 
incubated with  the  substrate  solution,  which  contained 3'3'- 
diaminobenzidine for 1 min and washed with water and weakly 
counterstained  with hematoxylin. Sections  that had been incubated 
with SP2 culture  supernatant served as a negative control.  Bi- 
otinylated horse anti-mouse IgG, avidin, and biotin were purchased 
from Vectastain (Burlingame, CA). 
Cloning and DNA Sequencing.  A ~gt11 expression cDNA li- 
brary prepared with mRNA from human breast carcinoma  cell line 
ZK-75-1 (Clontech, Palo Alto, CA) was screened with M31-15 as 
described (23). DNA of the resulting phage clone, MKP-1, was 
purified and the cDNA portion (1.1-kb fragment) was excised  with 
EcoRI and recloned into the EcoRI site of plasmid pUC118 (24) 
to construct plasmid pTB1352. Cloned cDNA was digested with 
appropriate restriction endonucleases  to generate small fragments. 
The fragments were subcloned into plasmid pUC118 and pUC119 
vectors. Single-stranded DNA was prepared by contransfecting 
helper phage KO7, and the nucleotide sequences were determined 
by the dideoxynucleotide  chain termination method (25) using ap- 
propriate synthetic oligonucleotide  primers. Both strands were then 
sequenced and all restriction sites used for subcloning were crossed. 
The sequence similarity of MRP-1, TAPA-1, CO-029,  ME491, 
CD37, and Sm23 cDNA was identified by a computer search of 
GenBank Genetic Sequence Database tel 67 using MSAP (Mitsui 
Knowledge Ind., Tokyo, Japan). 
Results 
Selection of mAb M31-15, Inhibiting MACIO Motility.  Hy- 
bridomas were produced after immunization of BALB/c mice 
with MAC8 cells. About 3,000 hybridoma supernatants were 
screened in a penetration assay that measured the ability of 
MAC10 cells to penetrate the Transwell membrane pores (5). 
mAb M31-15 (isotype IgG1) was found to show the strongest 
effect on inhibition of MAC10 motility. The effect of mAb 
concentration was dose dependent and led to constant inhi- 
bition at 1/xg/ml (Fig.  1). Control mouse IgG showed no 
inhibitory effect on cell motility regardless of concentration. 
Inhibition of Phagokinetic Motility of Various Cancer Cells by 
mAb M31-15.  Phagokinetic motility of various kinds of 
cancer cells was tested using the gold particle coating method 
described previously (7). Areas of the particle-clear  zone for 
cancer cells were measured after a 16-h incubation, and the 
average area was calculated.  The area of tracks swept out by 
the moving cells was reduced by 50-77%, as compared with 
the controls (Table 1).  The controls contained mouse IgG 
(1/zg/ml) instead of mAb M31-15. A typical example of in- 
hibition of MAC10 phagokinetic motility in the presence of 
M31-15 is shown in Fig. 2. 
Expression of  MRP-I on Various  Kinds of Cells by Cytofluorom- 
etry.  A variety of cancer and fetal cell lines were analyzed 
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Figure 1.  Dose-dependent  effect of mAb M31-15 on cell penetration. 
Cell penetration was determined with MAC-t0 cells in the lower chamber 
of  Transwell. The constant inhibitory  effect was produced by M31-15 con- 
centrations  of 1 /xg/ml. 
for reactivity with mAb M31-15 (Table 2). Most of the solid 
tumor cell lines except hepatocellular carcinomas were reac- 
tive, but two Burkitt's lymphoma lines were not reactive, 
which is strikingly different from the homologous TAPAol 
antigen (26).  Mouse melanoma BL6 and F1 had no reaction 
Table  1.  Inhibitory Effect on Phagokinetic Motility  of Various 
Cancer Cell Lines  by M31-15 
Areas 
Cell line  Control  M31-15 
itmZ +_. SD 
MAC10  9,820  _+  3,010  2,250  _+  760 
QG-90  4,310  _+  1,730  1,650  +_  690 
PC-9  5,320  _+  1,950  1,610  _+  590 
SK-LU-1  3,510  _+  1,050  1,490  _+  420 
KATOIII  4,250  _+  1,640  2,130  _+  820 
Estimated by average area of tracks on gold particle-coated  surface, as 
described in Materials and Methods.  Data are calculated from 100 un- 
selected cells. Mouse IgG was used as control at the same concentration 
(1/zg/ml). 
with mAb M31-15 (Table 2), so we did not begin the experi- 
ment of whether M31-15  could inhibit lung metastasis of 
highly variant BL6  (6,  20). 
Detection Of MRP-1  Antigen  in Formalinfixed Paraffin Sec- 
tions of Various Kinds of Cancers by Immunohistochemical Ex- 
amination.  We tested 50 lung cancers, 15 gastric cancers, 15 
colon cancers, 15 hepatocellular cancers, and 15 breast cancers. 
MILP-1  antigen was not found in any kinds of tissue sec- 
tions, in spite of high incidence of MIA31-15-positive cell 
lines by cytofluorometry. MRP-1 antigen was thought to be 
so fragile that it was probably not conserved in the formalin- 
fixed paraffin sections. 
Characterization of  Epito~ Recognized by M31-15.  The target 
antigen for M31-15  was not detected in glycolipid extracts 
Figure 2.  Effect  of mAb M31-15 on motility of MAC-10 cells as determined by pharmacokinesis from the gold colloid method. (a) MAC-t0 cell 
motility in medium containing M31-15 (1 #g/ml). (b) MAC-10 cell motility in medium containing mouse IgG (1 #g/ml). 
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Surface 
Cell line  Histology  expression 
MAC10  Lung adenocarcinoma  +  + 
PC-14  Lung adenocarcinoma  +  + 
PC-9  Lung  adenocarcinoma  +  + 
A-549  Lung alveolar  cell ca.  +  + 
KATOIII  Gastric ca.  +  + 
AZ521  Gastric ca.  +  + 
PLC/PKF/5  Hepatocellular ca. 
HEP-G2  Hepatocellular ca.  - 
MIA PaCa-2  Pancreatic ca.  +  + 
BxPC-3  Pancreatic ca.  +  + 
ZK-75-30  Breast ca.  +  +  + 
MCF-7  Breast ca.  +  + 
COLO201  Colon ca.  +  + 
Hela  Uterine Ca.  +  + 
KB  Nasopharyngeal ca.  +  + 
A-431  Epidermal ca.  + 
HEL  Erythroleukemia  + 
IM-9  Lymphoblastoma  - 
HL-60  Promyelocytic leukemia  - 
Jlll  Monocytic leukemia  +  + 
U266  Myeloma  - 
Daudi  Burkitt's lymphoma  - 
Karl  Burkitt's lymphoma  - 
G361  Melanoma  + 
T98G  Glioma  +  + 
Flow 7000  Fibroblast  +  + 
WI-38  Fetus lung  - 
IMK-90  Fetus lung 
WISH  Human amnion  +  + 
MEG-01  Megakaryocyte  - 
CEM  T  cell line  - 
F1  Mouse melanoma  - 
BL6  Mouse melanoma  - 
Determined by flowcytometry. Mean channel  fluorescence  intensity com- 
pared with negative control staining according to the following scale: 
-, 0-5%;  _+, 5-10%;  +,  10-50%;  + +,  50-90%;  + + +, >90%. 
resolved by both ELISA and TLC immunostaining (data not 
shown). However, on Western blotting of the soluble frac- 
tion of MAC10,  two bands (25  and 28  kD)  were dearly 
demonstrated (Fig. 3). These two bands were detected from 
various  cancer cells extracts  (Fig. 3).  Digestion of MAC10 
cell extracts with periodate had no effect on the migration 
and intensity of the two bands  (data not  shown),  so these 
two bands  were thought  to be not  glycosylated. 
Figure 3. Detection of  MRP-1 in 
the various cancer cell lines. The 
extracts of  various cancer  cell lines 
were treated in a boiling water 
bath for 5 min and subjected to 
slab gel (acrylamide  concentration, 
11%) electrophoresis  followed  by 
Western blotting  and immuno- 
staining. Lane I,  MIA PaCa-2; 
lane 2, MAC10; lane  3, HEL; lane 
4,  ZK-75-30. Migration of the 
molecular  weight  markers  is 
shown on the right. Arrowheads 
indicate the positions of 28- and 
25-kD bands. 
Isolation of  the MRP.1 cDNA.  Using M31-15, the cDNA 
clone MVlKP-1 was isolated from a •gtll  expression cDNA 
library prepared with mRNA from human breast carcinoma 
cell line ZR-75-1.  The length  of the  insert  carried in  the 
phage  vector  was  r  kb  when  checked  by  PCR  with 
universal primers specific to the phage DNA designed to am- 
plify the insert cDNAs. Partial nudeotide sequencing of this 
amplified fragment  showed the direction of the cDNA  in- 
sert.  For further analyses, the cDNA prepared from phage 
DNA  was  subdoned  into  the plasmid  pUC118  (24). 
Sequence Analysis of MRP-1  eDNA.  The nucleotide  se- 
quence of 1,120-bp MRP-1  cDNA  in MVlRP-1  was  deter- 
mined as shown in Fig. 4. A  search of the genetic sequence 
database (GenBank tel. 67) revealed a striking partial sequence 
similarity of MRP-1 to the members of a transmembrane pro- 
tein family consisting of TAPA-1 (26), CO-029 (27), ME491 
(28),  CD37  (29),  and Sm23 (30)  (Fig.  5). The similarly of 
MKP-1  to  them  was  43.5%,  35.1%,  26.4%,  22.3%,  and 
25.5%, respectively. The open reading frame of the MRP-1 
cDNA  was  speculated by considering  that  of the ~-galac- 
tosidase gene of Xgtll and comparing those of the members 
of the transmembrane protein family. The first ATG (at 112 
in Fig.  4) of the predicted open reading frame is flanked by 
sequences (TCACCATGC) that fulfill the criteria for initia- 
tion codons (CCA/GCCATGG) proposed by Kozak in 1984 
(31). This open reading frame of MRP-1 encodes a potential 
polypeptide of 228 amino acid residues with a predicted mo- 
lecular weight  of 25,419, which is consistent with the mo- 
lecular mass of the bands at 25 and 28 kD detected in Western 
blotting  described  above. 
Discussion 
Metastasis is among the most important problems in the 
therapy of the patients with various kinds of cancers. Almost 
all patients  with  disseminated  cancer are incurable by cur- 
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￿9 
CD37  WHYPQDWFQ~L  I  LRGNGSEA  RVPC~JSCYNLSATN  ST  I  LD K[VJI  LPQLSRLGHL 
R~LV  IIV~  AC~J  VAFGV  Sm23  ~JA KGPDDY  RGNVLV  ~  PASCKEE  LTYTEGCVSVFG 
24O  26O 
C0-029  O  LA  NLII~J  V  I  l  I  SFG~JA)V  I  ILGLVF  MV  YC  NK 
ME49|  GW L RIK~N V L V  V~'~  AAALG  I~F  V IG ' VF~CCLLJV K  FRSGYEVM 
CD37  ARSRHSAD~TC  VPAESH  Y  AARRA  RBGGTTTL  P 
TAPA-  1  L~]S G~L  Y L-II~  GIAAIVVJ_~VIMIFEMIL  M V[~C C G[~  RNSSVY 
Sm23  CF~JFQL LS  I  V  I~'~C C LG RQ I[J.JK E Y(~N V 
780  Figure 4.  Nucleotide  and deduced 
223  amino acid sequence of MRP-1 cDNA. 
840  The nucleotide sequence of the Ll-kb 
225  MP.P-1  cDNA was determined as de- 
scribed in Materials and Methods. The 
900  amino acid sequence encoded by the 
960  open reading frame is shown using the 
1020  single-letter amino acid code. Possible 
1080  asparagine-linked glycosylation site is 
X  120  underlined. 
Figure 5.  Amino acid sequence sim- 
ilarities. MRP-1 was aligned with the 
CO-029, ME491, CD37, TAPA-1,  and 
Sm23 proteins. Identities between any 
four of the proteins  are boxed.  Gaps 
were  created  by MSAP  program  to 
permit best alignment. The predicted 
transmembrane  domains proposed by 
Szala et al. (27) are overlined. 
1351  Miyake  et al. rently known methods, and the metastatic dissemination of 
tumor cells to secondary distinct sites requires highly motile 
behavior. Despite various kinds of specific antitumor defense 
mechanisms, tumor cells surviving in the blood and lymph 
vessels must be resistant to the shear stresses arising in the 
vascular bed, the frictional forces arising between their periph- 
eries and vessel walls,  as well as have the ability to traverse 
capillaries that generally are rigid and smaller in diameter then 
tumor cells (2, 32).  However, the biochemical mechanisms 
regulating such invasive tumor cell motility are poorly un- 
derstood.  Motility is  an essential  cellular function closely 
related to the process of tumor metastasis and at least plays 
a very important role in tumor invasion and metastasis.  Inhi- 
bition of tumor cell motility may have the possibility of leading 
to conquering tumor cell metastasis. 
Birchmeier et al. (33) studied the correlation between cell 
adhesion and metastatic potential of tumor cells by use of 
mAbs that inhibit these phenotypes. They found that var- 
ious mAbs affected phenotypic characteristics of melanoma 
cells such as adhesion, growth, migration, and morphology, 
but the molecular basis of the effect of these mAbs was not 
clearly shown. In the present study, this approach was used 
to establish motility-inhibiting mAbs after immunization of 
mice with human cancer cell lines characterized by high mo- 
tility. Screening and selection of mAbs were performed based 
on the inhibition of tumor cell motility as measured by a 
modified Boyden Transwell chamber. Through this proce- 
dure, we obtained various mAbs that inhibited penetrating 
activity; M31-15  showed the strongest inhibition.  M31-15 
reacted with most human cancer cell lines,  especially solid 
tumor cell lines (Table 2), and many of them expressed two 
25- and 28-kD proteins detected by Western blotting (Fig. 
3).  These two species were not affected by the peroxidase 
digestion, suggesting that MRP-1 was not glycoslated (data 
not shown). The predicted molecular mass of MRP-1 is 25.4 
kD, which coincided with the protein detected at 25  kD. 
The protein detected at 28 kD suggests the existence of the 
other member of the family, which is immunoreactive with 
M31-15.  This 28-kD species may be the NH2-teriminal ex- 
tended form of MRP-1 translated from the other protein (CTG 
at 43) upstream of the first ATG at 112, as shown in the case 
of basic fibroblast growth factor gene (34). 
The mechanism of motility inhibition by M31-15  is not 
clear. MRP-1 might be a receptor for a yet-to-be discovered 
member of the integrin family. The sequence of MRP-1 does 
not show any similarity to known integrin family receptors, 
but  shows  striking  partial  similarity  to  CD37,  ME491, 
TAPA-1, CO-029, and Sm23 (26) (Fig. 5). Very recently these 
molecules were found to form a new family of transmem- 
brahe type cell surface proteins (26). CD37 is highly expressed 
in human B cells and at lower levels in other hematopoietic 
cell types (35).  Anti-CD37 antibodies have been shown to 
inhibit the mitogenic effect of anti-CD20 plus B cell growth 
factor on B cells as well as stimulate the mitogenic effect of 
anti-Ig antibodies on these cells (36).  ME491  is expressed 
during the early stages of melanoma but is downregulated 
during later stages of melanoma, which are more aggressive 
and adaptable to tissue culture (37).  TAPA-1 is the cell sur- 
face protein expressed on most but not all human cell lines, 
and this antibody has a marked antiproliferative effect on many 
lymphoid cell lines (26).  CO-029 antigen is found to be ex- 
pressed on gastric, colon, rectal, and pancreatic carcinoma, 
except on most normal tissues  (38).  mAbs against CO-029 
have been shown to mediate antibody-dependent cell-mediated 
cytotoxicity in vitro, but had no effect on the growth of human 
colorectal carcinoma and melanoma lines (39). Sm23 is found 
as the integral membrane protein ofSchistosoma mansoni. The 
function of Sm23 has not been clarified (30). The amino acid 
sequence of MRP-1 shows the highest similarity to TAPA-1 
at 43.5%, but unlike TAPA-1, MRP-1 has little effect on cell 
growth of some kinds of tumor cell lines, including MAC10 
(data not shown). As shown in Table 1 and Figs.  1 and 2, 
MKP-1 is thought to be closely related to motility. MRP-1 
is expressed on many but not all cancer cell lines (Table 2), 
and M31-15  inhibits motility of some of these cell lines in 
the phagokinetic tract assay (Table 1). It is unknown whether 
CD37 (29), ME491 (28), TAPA-1 (26), and CO-029 (27) have 
effects on cell motility. We are going to study what kind 
of structure common to these families has an essential effect 
on cell motility with synthetic peptides. 
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